Ginkgo Bioworks Holdings, Inc. (DNA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.7200 |
| Open | 1.7800 |
| Bid | 1.8100 x 45900 |
| Ask | 1.8200 x 45900 |
| Day's Range | 1.7800 - 1.8700 |
| 52 Week Range | 1.1200 - 3.5200 |
| Volume | |
| Avg. Volume | 21,626,577 |
| Market Cap | 3.799B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6600 |
| Earnings Date | Nov 14, 2023 - Nov 18, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.02 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DNA
Related Research
- Ginkgo Bioworks Holdings, Inc.Daily – Vickers Top Buyers & Sellers for 05/23/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
PR NewswireConcentric By Ginkgo and Texas A&M University Awarded USDA NIFA AFRI Grant to Conduct Genomic Animal Research to Prevent Zoonotic Disease Spillover
Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and Texas A&M University today announced they have been jointly awarded a research grant from the U.S. Department of Agriculture's Animal and Plant Health Inspection Service (USDA APHIS) via the National Institute of Food and Agriculture, Agriculture and Food Research Initiative (NIFA AFRI) to study SARS-CoV-2 in white-tailed deer populations in Texas.
TipRanks‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $5
Along with the markets’ recent pullback, so has Cathie Wood’s flagship Ark Innovation ETF (ARKK) handed back some of the year’s prior gains. Nevertheless, it has still outpaced the broader markets this year. And despite growing bearish macro concerns, looking at how Wood expects the landscape to shape up, the ARK Invest CEO is optimistic her innovation-first approach will continue to deliver. “I do think that what’s happening this year is that the market is starting to look over the Fed’s moves…
PR NewswireEnsovi Leverages Ginkgo Enzyme Services to Optimize Cell-Free Carbon Fixation Process for Biomanufacturing
Ensovi Inc., which has invented an efficient, cell-free biomanufacturing platform that transforms waste CO2 to organic chemicals, today announced a new partnership with Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity. Ensovi will leverage Ginkgo Enzyme Services to help optimize its platform for the cell-free transformation of carbon dioxide (CO2) into Acetyl-CoA, which can then be converted into many other products, such as precursors to f
